Skip to main content

What the FDA labels say about taking them together

Abacavir and cabozantinib

Cabozantinib's FDA label (Cometriq) of October 18, 2025 names abacavir in its drug interactions section; the abacavir labels PlainMeds reads (2) do not name cabozantinib. The cabozantinib label: “Monitor patients for increased toxicity when MRP2 inhibitors are co-administered with COMETRIQ.”

Check it at the source: the abacavir FDA label on DailyMed (effective July 17, 2025, Mylan Institutional Inc.); the cabozantinib FDA label on DailyMed (effective October 19, 2025, Exelixis, Inc.).

What does the abacavir label say about cabozantinib?

Abacavir's label (effective July 17, 2025) and its 1 other brand-application label do not name cabozantinib in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Abacavir Sulfate), Mylan Institutional Inc., effective July 17, 2025 (SPL set 80c1702a-973c-436a-90f8-69b29674dca0), via openFDA; the full label on DailyMed

What does the cabozantinib label say about abacavir?

Cometriq label (Exelixis, Inc., October 18, 2025), drug interactions

Monitor patients for increased toxicity when MRP2 inhibitors (e.g., abacavir, adefovir, cidofovir, furosemide, lamivudine, nevirapine, ritonavir, probenecid, saquinavir, and tenofovir) are co-administered with COMETRIQ [see Clinical Pharmacology ( 12.3 )].

Source: FDA drug label (Cometriq, NDA203756), Exelixis, Inc., effective October 18, 2025 (SPL set 1a0c3bea-c87b-4d25-bb44-5f0174da6b34), via openFDA

Source: FDA drug label (CABOMETYX), Exelixis, Inc., effective October 19, 2025 (SPL set 3850cce2-6137-42e5-a792-d318c4a4b3b5), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

12Abacavir generic labelers
0Cabozantinib generic labelers
AbacavirCabozantinib
Labeled forHIVn/a
Boxed warningYesNo
Pharmacy cost (NADAC)$0.546 per tablet 300 mg tabletn/a
Shortage nowNo current entryNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?